Innoviva Inc (FRA:HVE) Stock Price, Trades & News

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	2.27
Equity-to-Asset	0.73
Debt-to-Equity	0.2
Debt-to-EBITDA	0.42
Interest Coverage	9.21
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.04	Distress Grey Safe
Beneish M-Score	-2.25	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	11.7
	3-Year EBITDA Growth Rate	10.5
	3-Year EPS without NRI Growth Rate	113.5
	3-Year FCF Growth Rate	1.3
	3-Year Book Growth Rate	24.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-18.16
	Future 3-5Y Total Revenue Growth Rate Estimate	7.77

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	28.65
	9-Day RSI	35
	14-Day RSI	38.92
	3-1 Month Momentum %	3.06
	6-1 Month Momentum %	19.53
	12-1 Month Momentum %	27.85

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	21.13
	Quick Ratio	20.07
	Cash Ratio	16.74
	Days Inventory	212.3
	Days Sales Outstanding	23.73
	Days Payable	28.54

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.6
	Shareholder Yield %	10.43

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	83.09
	Operating Margin %	38.15
	Net Margin %	119.89
	EBITDA Margin %	153.03
	FCF Margin %	43.5
	OCF Margin %	43.62
	ROE %	51.61
	ROA %	33.67
	ROIC %	13.88
	3-Year ROIIC %	-18.6
	ROC (Joel Greenblatt) %	1194.84
	ROCE %	44.92
	Years of Profitability over Past 10-Year	10
	Moat Score	5
	Tariff Resilience Score	8

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	3.49
	Forward PE Ratio	5.41
	PE Ratio without NRI	4.35
	Shiller PE Ratio	8.46
	Price-to-Owner-Earnings	3.11
	PS Ratio	4.23
	PB Ratio	1.15
	Price-to-Tangible-Book	1.35
	Price-to-Free-Cash-Flow	9.73
	Price-to-Operating-Cash-Flow	9.7
	EV-to-EBIT	1.95
	EV-to-EBITDA	1.87
	EV-to-Revenue	2.86
	EV-to-Forward-Revenue	2.76
	EV-to-FCF	6.58
	Price-to-GF-Value	1.02
	Price-to-Projected-FCF	0.5
	Price-to-Median-PS-Value	0.92
	Price-to-Graham-Number	0.51
	Price-to-Net-Current-Asset-Value	5.58
	Price-to-Net-Cash	13.19
	Earnings Yield (Greenblatt) %	51.28
	FCF Yield %	11.83
	Forward Rate of Return (Yacktman) %	-1.48

Financials (Next Earnings Date:2026-08-06 Est.)

Annual Quarterly TTM

FRA:HVE's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Innoviva Inc Executives

Details

GF Value™: €17.79

FRA:HVE

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with HVE. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	361.436
	EPS (TTM) (€)	5.165
	Beta	0.6218
	3-Year Sharpe Ratio	0.75
	3-Year Sortino Ratio	1.44
	Volatility %	34.42
	14-Day RSI	38.92
	14-Day ATR (€)	0.297811
	20-Day SMA (€)	18.925
	12-1 Month Momentum %	27.85
	52-Week Range (€)	14.2 - 21.2
	Shares Outstanding (Mil)	73.81

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Innoviva Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Innoviva Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings results for 2026	2026-11-05	In 96 days
Second quarter earnings results for 2026	2026-08-06	In 5 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-08 13:20	19.50 (+3.17%)
First quarter earnings results for 2026	2026-05-06	19.50 (+0.00%)
Oppenheimer 36th Annual Healthcare Life Sciences Conference	2026-02-26 10:00	20.20 (+3.06%)
Annual report for 2025	2026-02-25	19.80 (+0.51%)
Fourth quarter earnings results for 2025	2026-02-25	19.80 (+0.51%)
37th Annual Piper Sandler Healthcare Conference	2025-12-02 16:30	18.10 (-1.63%)
Third quarter earnings results for 2025	2025-11-05	15.50 (+0.00%)
H.C. Wainwright 27th Annual Global Investment Conference	2025-09-08 13:00	17.80 (+0.00%)

Show

Entries

Innoviva Inc Frequently Asked Questions

What is Innoviva Inc(FRA:HVE)'s stock price today?

The current price of FRA:HVE is €18.20. The 52 week high of FRA:HVE is €21.20 and 52 week low is €14.20.

When is next earnings date of Innoviva Inc(FRA:HVE)?

The next earnings date of Innoviva Inc(FRA:HVE) is 2026-08-06 Est..

Does Innoviva Inc(FRA:HVE) pay dividends? If so, how much?

Innoviva Inc(FRA:HVE) does not pay dividend.

Press Release

	Subject	Date
	Nortiva Bio Launches to Develop Long-Acting Oral Medicines	2026-06-18
	Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets	2026-06-16
	Innoviva to Participate in Upcoming Investor Conferences	2026-06-01
	Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress	2026-02-25
	Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference	2026-02-19
	U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents	2025-12-12
	Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea	2025-12-11
	Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference	2025-11-25
	Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress	2025-11-05
	Antheia Appoints Eric d'Esparbes as Chief Financial Officer	2025-10-21

10/Page

Articles on Innoviva Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.